RecruitingRecruiting
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
NCT03492151 · Ohio State University Comprehensive Cancer Center
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Confocal Laser Endomicroscopy as an IMaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
About this study
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtained during the clinic visit or prior to their EUS. EUS-guided nCLE imaging is first performed (B) followed by EUS-guided FNA and aspiration of cyst fluid. The cyst fluid is analyzed for CEA and cytology. As per institutional standard of care, the cyst fluid is also sent for molecular analysis. The results of the cyst fluid molecular analysis (B) will be utilized for the most likely diagnosis. Based on institutional multidisciplinary tumor board meetings, surgery is performed as indicated (C). Surgical histopathology serves as "gold standard" for diagnosis. It is anticipated that the majority of patients will undergo surgical resection after their EUS.
Eligibility criteria
Inclusion Criteria:
* Patient age 18 years or older
* All patients referred for EUS-FNA of accessible PCL where surgery is contemplated
* Minimum cyst size should be ≥ 2.0 cm as determined by prior cross-sectional imaging studies
Exclusion Criteria:
* Unable to obtain informed consent
* Unable to tolerate the procedure
* Women with known pregnancy at time of procedure
* Patient age less than 18 years
* Bleeding diathesis
* Known allergy to fluorescein
* Prior pancreatic cancer
* Prior pancreatic surgery
Study design
Enrollment target: 500 participants
Age groups: adult, older_adult
Timeline
Starts: 2018-10-01
Estimated completion: 2026-12-31
Last updated: 2025-08-22
Primary outcomes
- • Accuracy of PCL diagnosis (48 months)
- • Accuracy of risk-stratification of IPMNs (48 months)
Sponsor
Ohio State University Comprehensive Cancer Center · other
With: American College of Gastroenterology, The National Pancreas Foundation
Contacts & investigators
ContactMegan Fry · contact · Megan.Fry@osumc.edu · 614-293-1056
ContactDiana Burke · contact · Diana.Burke@osumc.edu
InvestigatorSomashekar Krishna, MD, MPH · principal_investigator, Ohio State University
All locations (10)
Mayo Clinic Scottsdale CampusRecruiting
Scottsdale, Arizona, United States
Stanford HospitalRecruiting
Stanford, California, United States
Yale School of MedicineRecruiting
New Haven, Connecticut, United States
Parkview Hospital RandalliaActive Not Recruiting
Fort Wayne, Indiana, United States
The Johns Hopkins HospitalRecruiting
Baltimore, Maryland, United States
Beth Israel Deaconess Medical CenterRecruiting
Boston, Massachusetts, United States
NYU Langone HealthRecruiting
Garden City, New York, United States
Icahn School of Medicine at Mount SinaiRecruiting
New York, New York, United States
The Ohio State University Wexner Medical CenterRecruiting
Columbus, Ohio, United States
Baylor College of MedicineRecruiting
Houston, Texas, United States